EUVIMEDEUVIMED entdecken
Crossref

Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance

Yuelun Xu, Fengling Zhang, Miaomiao Li, Huimin Zhang, Yuhong Yuan, Siying Lin, Liuxuan Yao, Shunfang Xu, Tao Yuan, Houzong Yao iD

Dalton Transactions · 2025

DOI: 10.1039/d4dt03249g ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dalton Transactions, 2025. Verfasst von Yuelun Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China. tyuan@jxnu.edu.cn. Hauptthemen laut MEDLINE: Prodrugs, Boron Compounds, Antineoplastic Agents, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel platform combining light-triggered activation and organelle-targeted platinum( iv ) prodrugs was developed to overcome chemotherapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsBoron CompoundsAntineoplastic AgentsDrug Resistance, NeoplasmOrganoplatinum CompoundsOrganellesPlatinumHumansCell Line, TumorDrug Screening Assays, AntitumorCell SurvivalCell Proliferation

Substanzen

ProdrugsBoron Compounds4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneAntineoplastic AgentsOrganoplatinum CompoundsPlatinum

Autor:innen und Institutionen

  • Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China. tyuan@jxnu.edu.cn.
  • Jiangxi Province Key Laboratory of Natural and Biomimetic Drugs Research, School of Health, Jiangxi Normal University, Nanchang 330022, China.

ORCID-Profile: Houzong Yao

Förderung

  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Xu, Y., Zhang, F., Li, M., Zhang, H., Yuan, Y., Lin, S., Yao, L., Xu, S., Yuan, T., & Yao, H. (2025). Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance. Dalton Transactions. https://doi.org/10.1039/d4dt03249g

Vancouver

Xu Y, Zhang F, Li M, Zhang H, Yuan Y, Lin S, et al. Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance. Dalton Transactions. 2025. doi:10.1039/d4dt03249g

BibTeX
@article{Xu2025,
  author = {Xu, Yuelun and Zhang, Fengling and Li, Miaomiao and Zhang, Huimin and Yuan, Yuhong and Lin, Siying and Yao, Liuxuan and Xu, Shunfang and Yuan, Tao and Yao, Houzong},
  title = {Organelle-targeted BODIPY-conjugated platinum( iv ) anticancer prodrugs for overcoming drug resistance},
  journal = {Dalton Transactions},
  year = {2025},
  doi = {10.1039/d4dt03249g}
}
Kostenlos starten →